PARKINSON DISEASE (PD) and other involuntary movement disorders YACOUB BAHOU MD Professor in Neurology at the University of Jordan Parkinson disease: introduction; etiology and pathogenesis; other akinetic-rigid syndromes; pathology and pathophysiology; epidemiology; clinical manifestations; treatment

II) Drug-induced movement disorders

III) Tremor

IV) Huntington disease and other causes of choreaV) Ballism

VI) Dystonia

VII) Myoclonus

VIII) Tics

I) Parkinson disease

1. Introduction

Most common <u>neurodegenerative</u> <u>movement disorder</u> and is the most common form of parkinsonism, the clinical syndrome characterised principally by bradykinesia and rigidity

Features of <u>other</u> <u>idiopathic</u> <u>parkinsonian</u> <u>syndromes</u>
(with the exception of vascular parkinsonism where the cause is known) are shown in the table

TABLE 16-1. Parkinsonian Syndromes

Parkinsonian Syndrome Distinguishing Clinical Features Progressive supranuclear palsy Supranuclear ophthalmoplegia, with greatest limitation of downward gaze; axial rigidity; early falls due to rigidity, impaired postural reflexes, neck hyperextension, and inability to look down Corticobasal ganglionic degeneration Limb apraxia; cortical sensory impairment; alien-limb phenomenon; asymmetric rigidity; dementia Diffuse Lewy body disease Early dementia; prominent visual hallucinations; cognitive fluctuations; extreme sensitivity to extrapyramidal side effects of antidopaminergic neuroleptic drugs Vascular parkinsonism "Lower-half" parkinsonism in which rigidity in the legs is greater than in the arms, resulting in slow, shuffling gait Multiple system atrophy Early and prominent features of autonomic dysfunction (MSA-A); cerebellar dysfunction (MSA-C); parkinsonism refractory to levodopa (MSA-P); high-pitched, quivering dysarthria

2. Etiology and pathogenesis

Although the ultimate <u>cause</u> of <u>Parkinson's</u> <u>disease</u> is <u>unknown</u>, other, generally rarer, <u>akinetic-rigid</u> <u>syndromes</u> have an <u>identified</u> <u>etiology</u>(next section)

The recognition that <u>MPTP</u>, a <u>synthetic heroin by-product</u> , could produce <u>acute parkinsonism</u> has provided some insight into the etiology of Parkinson's disease itself.

The toxin <u>MPTP</u> <u>crosses</u> the <u>blood-brain</u> <u>barrier</u> and is <u>converted</u> to its active metabolite <u>MPP</u>+ by the enzyme monoamine oxidase type B(<u>MAO-B</u>) in glial cells.

<u>MPP+</u>, a <u>free</u> <u>radical</u> is concentrated in <u>dopaminergic</u> <u>neurons</u>, entering via the dopamine reuptake mechanism, thereby selectively <u>damaging</u> <u>these</u> <u>cells</u>.

<u>MPP+</u> is a <u>mitochondrial poison</u>, inhibiting complex I of the respiratory chain, and hence <u>impairing cellular energy</u> <u>production.</u> (figure)



Figure 12.1 MPTP and the aetiology of Parkinson's disease. The toxin MPTP crosses the blood–brain barrier and is converted to its active metabolite MPP+ by the enzyme monoamine oxidase type B (MAO-B) in glial cells. MPP+, a free radical, is concentrated in dopaminergic neurones, entering via the dopamine reuptake mechanism, thereby selectively radical, is concentrated in dopaminergic neurones, inhibiting Complex I of the respiratory chain, and hence impairing damaging these cells. MPP+ is a mitochondrial poison, inhibiting Complex I of the respiratory chain, and hence impairing cellular energy production.

The fact that an <u>unusual exogenous toxin</u> may lead to selective CNS damage and Parkinsonism has reinforced the view that <u>idiopathic Parkinson's disease</u> itself may be caused by <u>exposure</u> to a more <u>widely prevalent</u> <u>environmental factor</u>, as yet unidentified, perhaps <u>acting by a similar mechanism</u> to <u>MPTP</u> Further <u>support</u> for <u>environmental</u> <u>factors</u> includes the following:

- The disease is increasingly common with <u>age</u> (<u>mean</u> <u>age</u> of <u>onset</u> <u>about</u> <u>60</u> <u>years</u>)
- <u>Genetic</u> causative <u>factors</u> have been identified but a positive <u>family history</u> is relatively <u>unusual</u> in idiopathic Parkinson's disease
- There is a <u>weak association</u> between Parkinson's <u>disease</u> and various environmental factors, e.g. , <u>exposure</u> to <u>wood pulp</u> and <u>pesticides</u>

3. <u>Other akinetic-rigid syndromes</u>

* <u>Wilson disease</u>:

- This is a rare <u>autosomal</u> <u>recessive</u> defect of copper metabolism

- Levels of <u>serum copper</u> and <u>ceruloplasmin</u>, the copper transport protein, are <u>low</u> and <u>copper</u> is <u>deposited</u> in the <u>tissues</u>, particularly the liver and basal ganglia

- The disease may present in <u>childhood</u> with <u>cirrhosis</u>, or in <u>adolescence</u>, where the <u>neurological</u> <u>features</u> dominate - The <u>neurological features</u> include an akinetic-rigid syndrome, dystonia, cerebellar signs or sometimes neuropsychiatric manifestations, even frank psychosis

- Copper is also <u>deposited</u> in the <u>cornea</u>, as <u>Kayser-</u> <u>Fleischer</u> <u>rings</u>, detectable on slit lamp examination</u>



Kayser-Fleischer ring

Classification and external resources

A Kayser-Fleischer ring in a 32-year-old patient who had longstanding speech difficulties and tremor.



- The <u>diagnosis</u> of <u>Wilson's disease</u>, based on serum copper and ceruloplasmin, Kayser-Fleischer rings and, if necessary liver biopsy is important, as the condition is <u>treatable</u> and is <u>fatal without therapeutic intervention</u>

- The mainstay of <u>treatment</u> are the <u>copper-chelating</u> <u>agents</u> trientine and penicillamine, <u>zinc</u> <u>supplementation</u>, and <u>restriction</u> of <u>copper-containing</u> foods such as liver, shellfish, and mushrooms

- <u>Earlier</u> treatment results in <u>better</u> long-term neuropsychiatric and hepatic <u>outcome</u>

- <u>Liver transplantation</u> may be necessary for patients with fulminant symptoms including <u>hepatic failure</u>

* <u>Traumatic</u>: '<u>Punch-drunk syndrome</u>'- <u>chronic head</u> <u>injury</u> in <u>boxers-</u> patients have parkinsonian features often in combination with cerebellar damage and cognitive deficits(<u>dementia pugilistica</u>)

* <u>Inflammatory</u>: <u>Postencephalitic</u> <u>Parkinsonism-</u> following the <u>epidemic</u> of <u>encephalitis</u> <u>lethargica</u> after World War I , patients developed a <u>chronic akinetic-</u> <u>rigid state</u>, with certain characteristic features, particularly <u>oculogyric crises</u> * <u>Neoplastic</u>: <u>tumours</u> of the <u>basal</u> ganglia presenting with contralateral <u>hemiparkinsonism</u> are extremely <u>rare</u>

* <u>Vascular</u>: <u>Multiple</u> <u>lacunar</u> <u>infarcts</u> may occasionally result in <u>pseudoparkinsonian</u> features, but usually in association with <u>pyramidal</u> and <u>cognitive</u> <u>dysfunction</u>

* <u>Drugs</u>: Neuroleptics, antiemetics(metoclopramide), amiodarone

* <u>Toxins</u>: MPTP, manganese, chronic carbon monoxide poisoning

4. <u>Pathology</u> and <u>pathophysiology</u>

The precise source of PD is not known, but the essential <u>motor manifestations</u> of the disease are due to <u>degeneration</u> of <u>dopaminergic neurons</u> in the <u>substantia nigra pars compacta</u> (figure)

The key <u>histopathologic finding</u> of PD is the <u>Lewy body</u>, which is an <u>alpha-synuclein</u> containing <u>eosinophilic</u> <u>cytoplasmic inclusion</u> that accumulates in neurons in the brainstem,cerebral cortex, and sympathetic autonomic ganglia

Figure 12.2 Loss of pigment in the substantia nigra. (a) Normal; (b) Parkinson's disease.

(2)



Figure 12.3 The Lewy body (arrowed).

The <u>dopaminergic neurons</u> primarily affected in Parkinson's disease are those <u>projecting</u> from the <u>substantia nigra</u> of the midbrain <u>to</u> the <u>striatum</u> of the <u>basal ganglia</u>(caudate nucleus and putamen)

<u>Macroscopically</u>, <u>atrophy</u> of the <u>substantia</u> <u>nigra</u> in <u>advanced</u> <u>Parkinson's</u> <u>disease</u> is recognizable by <u>loss</u> of the characteristic <u>melanin</u> <u>pigmentation</u> of this region



<u>Microscopically</u>, severe <u>neuronal</u> <u>loss</u> is demonstrable in the substantia nigra, remaining neurons often containing a distinctive <u>intracellular</u> <u>inclusion</u>, the <u>Lewy</u> <u>body</u>

<u>Symptoms</u> of Parkinson's disease <u>appear</u> when about <u>60-80%</u> of nigrostriate <u>dopaminergic</u> <u>neurons</u> have been <u>lost</u>

<u>Pathophysiologically</u>, <u>damage</u> to <u>dopaminergic</u> <u>pathways</u> leads to an <u>imbalance</u> in the extrapyramidal system in <u>favour</u> of <u>cholinergic</u> and other neurotransmitter <u>mechanisms</u> *<u>Normal dopaminergic pathways</u> are <u>balanced</u> <u>by</u> those utilizing other neurotransmitters, predominantly <u>acetylcholine</u> (ACH)

* <u>Dopaminergic deficiency</u> or <u>cholinergic excess</u>, resulting in an <u>akinetic-rigid syndrome</u>, e.g., idiopathic Parkinson's disease or drug-induced Parkinsonism

(Phenothiazines, Haloperidol and related drugs are <u>neuroleptics</u> and are <u>dopamine</u> <u>antagonists</u>)

* <u>Dopaminergic excess</u> or <u>cholinergic deficiency</u> result in <u>excessive involuntary movements- dyskinesia</u>, e.g., due to <u>overtreatment</u> of <u>Parkinson's disease</u> with dopaminergic drugs, or to <u>degenerative</u> disease of <u>non-</u> <u>dopaminergic pathways</u>, as in <u>Huntington's disease</u> (which leads to <u>atrophy</u> of both <u>caudate nuclei</u>)



Normal-dopaminergic pathways balanced by those utilizing other neurotransmitters, predominantly acetylcholine (ACh).

Dopaminergic deficiency or cholinergic excess, resulting in an akinetic—rigid syndrome, e.g. idiopathic Parkinson's disease or drug-induced Parkinsonism (NB phenothiazines and related drugs are dopamine antagonists).

Dopaminergic excess or cholinergic deficiency, resulting in excessive involuntary movements – dyskinesia, e.g. due to overtreatment of Parkinson's disease with dopaminergic drugs, or to degenerative disease of non-dopaminergic pathways, as in Huntington's disease.

5. Epidemiology

PD is most common in <u>middle-aged</u> and <u>older patients</u>, affecting approximately 1% of people over 60 years

It is typically a <u>sporadic</u> disorder, but <u>hereditary</u> forms of PD due to <u>mutations</u> in <u>genes</u> such as PRKN, PINK1, LRRK2, and GBA may affect <u>younger patients</u>



Fig. 18.1 Cross-section of the midbrain.

6. <u>Clinical manifestations</u>

The <u>4 cardinal motor manifestations</u> of PD are tremor, rigidity, bradykinesia, and postural instability

Approximately 80 % of patients with PD have a <u>resting</u> <u>tremor</u>, which is characteristically <u>asymmetric</u>, involves the hands, recurs about 4 times per second (4 Hz), and is worse with distraction

A" <u>pill-rolling</u>" <u>tremor</u> involving the thumb and forefinger is classic(figure)



<u>Bradykinesia</u> or slowness of movement is often the most <u>disabling</u> feature of PD and involves both <u>axial</u> and <u>appendicular muscles</u>.

<u>Speech</u> and <u>swallowing</u> difficulties in PD are

manifestations of bradykinesia

<u>Rigidity</u> is an increase in muscle tone, which is equal in both flexion and extension of a body part, <u>different</u> <u>than</u> <u>spasticity</u>(table)

In patients with PD , <u>rigidity</u> tends to be <u>greater</u> in the <u>limbs</u> than in the trunk(figure)

Differences between spasticity and rigidity

Spasticity	Rigidity
Lesion in upper motor neuron	Lesion in basal ganglia and connections
Increased tone more marked in flexors in arms and extensors in legs	Increased tone equal in flexors and extensors
Increased tone most apparent early during movement ('clasp-knife effect')	Increased tone apparent throughout range of movement (Lead pipe rigidity)
Reflexes brisk with extensor plantars	Normal reflexes with flexor plantars





<u>Postural instability</u> is the final cardinal motor manifestation of PD: patients with advanced PD have difficulty with postural control and tend to <u>fall</u> <u>backward</u> when pulled from behind

PD also has important "<u>nonmotor</u>" features.

Rapid eye movement (<u>REM</u>) <u>sleep behaviour disorder</u> is characterised by violent enacting of dreams.The patient's bed partner will describe them as fighting, kicking, or running while asleep.

This <u>phenomenon</u> is <u>due</u> to the <u>failure</u> to <u>induce muscle</u> <u>atonia</u> in REM sleep and often <u>predates</u> <u>overt PD</u> by many years
Other non-motor symptoms include:

- <u>Depression</u>: is common and may arise independently of the degree of motor dysfunction

- <u>Hallucinations</u>: Vivid, formed <u>visual hallucinations</u> may occur, particularly at night, and need not necessarily indicate cognitive impairment or psychosis

 <u>Psychosis</u>: Worsening hallucinations and delusions may escalate to full-blown psychosis, particularly <u>in</u> <u>patients</u> who also have <u>cognitive impairment</u> - <u>Dementia</u>: Cognitive impairment is a common accompaniment of <u>advanced</u> <u>Parkinson's disease</u>

- <u>Sleep disorder</u>: Insomnia is common in Parkinson's disease and may relate to <u>immobility</u>, <u>mood</u> <u>disturbance</u>, <u>hallucinations</u> and various <u>sleep-related</u> behavioural and <u>movement</u> <u>disorders</u>

- <u>Autonomic symptoms</u>:

The skin may have a greasy seborrheic texture

<u>Constipation</u> is common, as are <u>bladder</u> <u>disturbance</u> and erectile dysfunction

Other autonomic features, e.g., <u>postural hypotension</u>, are relatively <u>milder</u> than in <u>multiple system</u> <u>atrophy</u>

- <u>Anosmia</u>: it is a feature of Parkinson's disease which may <u>antedate</u> the onset of <u>motor symptoms</u> by many years

7. <u>Treatment</u>

The most effective medical treatment of PD is <u>replacement</u> of <u>deficient endogenous</u> <u>dopamine</u> with <u>levodopa</u>.(Indeed, if this does not help, one should consider the possibility of other illnesses other than idiopathic PD)

Levodopa is combined with carbidopa, an inhibitor of peripheral dopa decarboxylase, which allows the <u>levodopa</u> to <u>cross</u> the <u>blood-brain</u> <u>barrier</u> and reach its target, while <u>reducing peripheral dopaminergic</u> <u>side effects</u> including nausea, vomiting and postural hypotension <u>Initially levodopa</u> is quite <u>effective</u> for most patients with PD, but <u>over time</u> it <u>loses</u> its <u>effectiveness</u>, and disabling <u>dyskinesias</u> develop

The <u>long-term</u> <u>treatment</u> of PD is complicated (table)

The <u>monoamine</u> <u>oxidase</u> <u>B</u> <u>inhibitors</u> rasagiline and selegiline may provide slight benefit to patients with PD and are often used in the <u>early stages</u> of the disease as <u>monotherapy</u> or as a <u>supplement</u> to levodopa

TABLE 16-2. Therapeutic Strategies in Parkinson Disease

Scenario/Problem

Initial treatment

Poor or no response to initial treatment

Tremor-predominant disease

Overnight or early morning bradykinesia

Levodopa-induced hallucinations

"Wearing off"

Dyskinesia

Therapeutic Approach

Levodopa, dopamine agonist, or MAO inhibitor

Increase levodopa dose and consider alternative diagnoses

Anticholinergic or amantadine

Consider overnight controlled-release preparation of levodopa

Discontinue concurrent therapy with anticholinergics, amantadine, selegiline, or dopamine agonists

Decrease dose of levodopa

Low-dose atypical antipsychotic (with quetiapine, clozapine, or pimavanserin)

More frequent dosing

Extended release formulation of levodopa

Add COMT inhibitor

Reduce dose of levodopa

Add or increase dose of dopamine agonist

Change dopamine agonist

Add amantadine

Consider deep brain stimulation

COMT, catechol O-methyl transferase; MAO, monoamine oxidase.

The <u>dopamine</u> <u>agonists</u> pramipexole and ropinirole are also options for the treatment of <u>mild</u> or <u>early PD</u>

These medications may improve symptoms and <u>reduce</u> <u>levodopa</u> <u>requirement</u>, thereby <u>minimizing</u> the longterm probability of <u>dopamine-related</u> <u>dyskinesias</u>

<u>Rotigotine</u> is a dopamine agonist available in <u>patch</u> <u>form</u> and is designed to prevent excessive fluctuation in drug levels <u>Other medications</u> are used for <u>specific applications</u> in PD :

*Anticholinergics including benztropine and trihexyphenidyl are used to treat tremor but generally have little effect on other PD symptoms *Amantadine is helpful in the management of dyskinesias and dystonia associated with PD *The catechol-O-methyl transferase inhibitor entacapone inhibits levodopa metabolism, thereby extending the duration of levodopa action in patients who experience "wearing off".

Drug treatments are summarized in the <u>table</u>

TABLE 16-3. Pharmacologic Treatment of Parkinson Disease			
Drug	Mechanism of Action	Dosing	Side Effects
Levodopa/carbidopa	Dopamine precursor/ dopa decarboxylase inhibitor	Start with a half of a 25/100 tablet bid; increase dose as needed; typically dosed 3–5 times a day	Anorexia, nausea, psychosis, hallucinations, orthostatic hypotension, dyskinesia
Trihexyphenidyl	Anticholinergic	Start with 1 mg bid–tid; increase to 4 mg tid as needed	Dry mouth, constipation, urinary retention, confusion, hallucinations, narrow-angle glaucoma
Benztropine	Anticholinergic	Start with 0.5–1 mg at bedtime; increase to 2 mg qid as needed	As above
Amantadine	NMDA antagonist	100 mg bid	Hallucinations, leg edema, <i>livedo reticularis</i>
Pramipexole	Dopamine agonist	Start with 0.125 mg tid; titrate gradually to 1.5 mg tid as needed	Lightheadedness, sleep attacks, pathologic gambling, and other impulse control disorders
Ropinirole	Dopamine agonist	Start with 0. 25 mg tid; titrate gradually to 1 mg tid as needed	As above
Rotigotine patch	Dopamine agonist	2 mg qd; titrate to 6 mg qd	As above, patch site reactions
Entacapone	COMT inhibitor	200 mg with each L-dopa dose	Nausea, diaphoresis, lightheadedness
Rasagiline	MAO-B inhibitor	1 mg qd	Dizziness, flulike syndrome
Selegiline	MAO-B inhibitor	5 mg bid	Confusion, orthostatic hypotension, nausea

COMT, catechol O-methyl transferase; MAO-B, monoamine oxidase B; NMDA, N-methyl d-aspartate.



Pergolide

Ropinirole

Apomorphine

Dopamine receptor

(0)

(0)

Dopamine

agonists

Enzymatic degradation

MAO-B—inhibited by

COMT—inhibited by

Selegiline

Entacapone

into vesicles

Dopamine o

0

release

Synaptic

deft

0

0

0

0)

0

Figure 12.6 Actions of drugs which improve dopaminergic transmission in Parkinson's disease. Amantadine, a weak antiparkinsonian drug, appears to act by several mechanisms. In addition to those illustrated which relate directly to dopaminergic transmission, there are also indirect effects via pathways utilizing other neurotransmitters, e.g. glutamate. <u>Deep brain stimulation</u> of the subthalamic nucleus (STN) and globus pallidus internus may be helpful in patients with <u>advanced disease</u>

II) Drug-induced movement disorders

Medications which <u>block dopamine receptors</u> including <u>antipsychotic medications</u> (both <u>traditional</u> dopamine blockers and <u>newer</u>, atypical agents) and the <u>promotility agent metoclopramide</u> may produce a variety of movement disorders

A) <u>Acute dystonic reactions</u>

They occur when patients are <u>introduced</u> to <u>dopamine-blocking medications</u> or given <u>high doses</u> of <u>dopamine</u> <u>blockers</u> to which they are not accustomed

Intermittent or sustained contraction in any of the muscles in the face, limbs, or trunk may occur

<u>Forced</u> <u>contraction</u> of the <u>extraocular</u> <u>muscles</u> and tonic deviation of the eyes may occur

Acute dystonic reactions are best <u>treated</u> with <u>anticholinergic</u> <u>agents</u> and <u>benzodiazepines</u>

This reaction is <u>short-lived</u> and does not produce longterm consequences

B) Parkinsonism

This may occur as the result of <u>long-term</u> <u>use</u> of any <u>neuroleptic</u> <u>agent</u>

The symptoms are <u>similar to</u> those seen in <u>Parkinson</u> disease, but <u>tremor</u> is <u>less common</u> and patients tend to be <u>less responsive to levodopa</u>

C) <u>Neuroleptic malignant syndrome</u>

This occurs when patients are <u>exposed</u> to <u>high</u> <u>doses</u> of <u>dopamine-blocking</u> <u>medications</u> or when <u>levodopa</u> or <u>dopamine</u> <u>agonists</u> are <u>withdrawn</u> <u>rapidly</u>

The <u>syndrome</u> <u>includes</u> fever, autonomic instability, encephalopathy, and muscular rigidity

The <u>offending agent</u> must be <u>stopped</u>, but a <u>combination</u> of bromocriptine, dantrolene, and benzodiazepines is usually <u>required</u> to <u>control</u> the <u>muscle</u> <u>rigidity</u>

D) <u>Tardive</u> <u>dyskinesia</u> (<u>TD</u>)

This is a disorder that occurs after <u>chronic exposure</u> to <u>dopamine-blocking agents</u>

<u>Commonly observed movements</u> include chewing , grimacing, lip smacking, and tongue thrusting The <u>limbs</u>, <u>trunk</u>, and even <u>diaphragm</u> may be <u>affected</u>

Treatment of TD is challenging:

- <u>Withdrawal</u> of the <u>offending agent</u> often makes the movements <u>worse</u>

- The dopamine-depleting agent <u>tetrabenazine</u> may be helpful

III) <u>Tremor</u>

Tremor is an <u>involuntary oscillatory movement</u> of a body part(arm, leg, head, jaw, lips, palate)

It can be divided into <u>resting</u> (occurring when the body part is at rest), <u>postural</u> (occurring when maintaining a fixed posture), or <u>action</u> (occurring on movement)

Postural and action tremors usually accompany each other

The term <u>intention</u> <u>tremor</u> is applied when an action tremor worsens as the body part approaches its target <u>Common types</u> and <u>causes</u> of <u>tremors</u> are:

- <u>Resting tremor</u>: idiopathic <u>Parkinson</u> disease, other parkinsonian syndromes

- <u>Postural/action tremor</u>: <u>essential</u> tremor, <u>physiologic</u> tremor, <u>drugs</u> (e.g., theophylline, beta-agonists), alcohol, <u>orthostatic</u> tremor

- <u>Intention tremor</u>: <u>cerebellum</u> and <u>cerebellar outflow</u> <u>tract dysfunction</u> (e.g. , infarction, multiple sclerosis, tumor, Wilson disease, drugs) <u>Essential tremor</u> (ET) is the <u>most common tremor</u> and overall, the most common movement disorder

It can begin at <u>any age</u> and tends to get <u>worse</u> over <u>time</u>

Because there is often a <u>family history</u>, the term "<u>familial</u> <u>tremor</u>" is sometimes applied

The tremor is a <u>postural</u> and <u>action tremor</u>, which involves the hands, head, and voice

It often <u>improves</u> with <u>small</u> <u>quantities</u> of <u>alcohol</u>, though this is not recommended as a treatment strategy The most <u>effective</u> <u>treatment</u> options are <u>propranolol</u> and <u>primidone</u>

<u>Deep brain stimulation</u> of the <u>ventral intermediate</u> <u>nucleus</u> of the <u>thalamus</u> may help patients with <u>disabling ET</u> refractory to medications IV) Huntington disease and other causes of chorea

<u>Chorea</u> is an irregular ,twisting or jerky movement of a group of muscles

In most cases, chorea <u>flows</u> from <u>one</u> <u>muscle</u> <u>group</u> to an <u>adjacent</u> <u>group</u> in a random-appearing pattern

Chorea is usually <u>accompanied</u> by <u>athetosis</u>, a writhing movement of the limbs

<u>Motor impersistence</u> often occurs with chorea: <u>two</u> <u>examples</u> are the darting tongue and milkmaid grip, which are seen in patients with Huntington disease (HD)

Causes of chorea

* <u>Hereditary</u>: Huntington disease(HD), HD-like syndromes, neuroacanthocytosis, dentatorubral pallidoluysian atrophy, Wilson disease

- * <u>Drugs</u>: neuroleptics, antiparkinsonian medications
- * <u>Toxins</u>: alcohol, anoxia, carbon monoxide
- * <u>Metabolic</u>: hyperthyroidism, nonketotic hyperglycemia, hepatocerebral degeneration
- * <u>Pregnancy</u>: chorea gravidarum

* <u>Immunologic</u>: SLE, antiphospholipid syndrome, poststreptococcal (Sydenham chorea)

* <u>Vascular</u>: caudate infarction or hemorrhage

<u>Huntington</u> <u>disease</u> (<u>HD</u>)

*Clinical manifestations

HD, an <u>autosomal dominant neurodegenerative</u> disorder is the most <u>important</u> and <u>serious</u> cause of chorea

HD is characterized by <u>chorea</u>, <u>cognitive</u> <u>impairment</u>, <u>dystonia</u>, and <u>psychiatric</u> <u>illness</u>

<u>Symptoms</u> usually appear <u>between</u> the <u>ages</u> of <u>35</u> and <u>45 years</u> and include the <u>triad</u> of chorea, behavioral changes or personality disorder(frequently obsessive-compulsive disorder), and dementia

The <u>three</u> may occur <u>together</u> at onset, <u>or one</u> may <u>precede</u> the <u>others</u> by years

* Diagnostic evaluation

<u>Diagnosis</u> is by personal and family history, clinical signs, imaging, and genetic testing

<u>Caudate atrophy</u>, sometimes severe, is the characteristic finding <u>on</u> magnetic resonance imaging (<u>MRI</u>)

<u>Definitive diagnosis</u> is made by finding an <u>expansion</u> of more than 40 cytosine-adenine-guanine <u>trinucleotide</u> <u>repeats</u> in the <u>HTT gene</u> on <u>chromosome 4</u>

Basal Ganglia

Horizontal Sections through Cerebrum







* <u>Pathology</u>

Pathologic examination shows severe <u>destruction</u> of the <u>caudate</u> and <u>putamen</u> (striatal and nigral GABAergic neurons) and loss of neurons in the cerebral cortex (layer 3)

The <u>molecular mechanisms</u> of HD are <u>unclear</u> but involve accumulation of abnormal intracellular proteins which triggers cell death

* Treatment

Pharmacologic management of dementia and chorea often involves <u>dopaminergic</u> <u>antagonists</u>, including <u>neuroleptic</u> <u>drugs</u>, but it is far from adequate

<u>Neuroleptics</u> can <u>ameliorate</u> the <u>chorea</u>, but the other <u>neuropsychiatric</u> <u>symptoms</u> ultimately prove <u>disabling</u>

Unfortunately, HD is a <u>progressive</u> and <u>ultimately</u> <u>fatal</u> disorder; death occurs 10 to 20 years after onset

Suicide is not rare in at-risk and early-onset HD patients

<u>Genetic</u> <u>counseling</u> is crucial

V) <u>Ballism</u>

Ballism is a <u>brief flinging movement</u> of a <u>limb</u>, most often unilateral (hemiballismus)

The classic <u>lesion</u> responsible for hemiballismus is an <u>ischemic stroke</u> in the <u>contralateral subthalamic</u> <u>nucleus</u>, though lesions in other components of the basal ganglia may be causative

In <u>many cases</u>, <u>ballism resolves</u> on its own, but <u>dopamine-blocking agents</u> may be helpful if this spontaneous improvement does not occur

VI) <u>Dystonia</u>

Dystonia is a <u>sustained contraction</u> of <u>agonist</u> and <u>antagonist muscles</u> producing twisting movements or abnormal postures

Dystonia may be <u>focal</u> (affecting one body part), <u>segmental</u> (affecting one region), or <u>generalized</u> (affecting multiple body parts)

The abnormal movements are <u>worsened</u> by <u>movement</u> and <u>relieved</u> by <u>sensory tricks</u> such as touching or stroking the affected body part <u>Focal dystonia</u> is more common in <u>adults</u>, and various body parts have characteristic dystonias

<u>Torticollis</u> is excessive contraction of the <u>neck muscles</u> resulting in a fixed head position; it is often quite painful

<u>Blepharospasm</u> involves sustained contraction of the <u>orbicularis</u> <u>oculi</u> and forced closure of the eyelids

<u>Spasmodic</u> <u>dysphonia</u> involves the <u>laryngeal</u> <u>muscles</u> and may result in choppy or strangled speech (<u>adductor</u> spasmodic dysphonia) or a breathy voice quality (<u>abductor</u> spasmodic dysphonia) <u>Writer's cramp</u> is a focal dystonia of the <u>hand</u> and <u>arm</u> <u>muscles</u> that prevents a patient from using a writing implement properly

In general, <u>botulinum</u> toxin <u>injections</u> are the best treatment option for focal dystonias <u>Generalized</u> <u>dystonias</u> are more common in <u>children</u> than in adults

The most common of these is **<u>DYT-TOR1A</u>** <u>**dystonia**</u>, an <u>autosomal</u> <u>dominant</u> disorder caused by a <u>mutation</u> in the <u>gene</u> that encodes the <u>protein</u> <u>torsin</u> <u>A</u>

DYT-TOR1A dystonia starts in <u>childhood</u> or <u>adolescence</u> and often begins in the <u>foot</u> and <u>leg muscles</u>

<u>Treatment options</u> include anticholinergic agents such as trihexyphenidyl, or baclofen, benzodiazepines and deep brain stimulation of the globus pallidus interna
The <u>dopa-responsive</u> <u>dystonias</u> are an important group of <u>childhood-onset</u> dystonias and are caused most often by a <u>mutation</u> in the <u>gene</u> encoding the enzyme <u>GTP</u> cyclohydrase <u>1</u>

Parkinsonism may accompany the dystonia

As the name suggests, this group of conditions is <u>responsive</u> to <u>dopamine</u>

For this reason, a <u>trial</u> of <u>levodopa</u> is warranted in all <u>children</u> who develop <u>dystonia</u>

<u>Dystonias</u> may also occur as a <u>manifestation</u> of <u>other</u> <u>central nervous system disorders</u> including Wilson disease, Parkinson disease, Huntington disease, anoxic brain injury, stroke, multiple sclerosis, and medicationinduced movement disorders

VII) Myoclonus

<u>Myoclonus</u> is a <u>sudden jerking movement</u> of a <u>muscle</u> that is sufficient to move a joint

<u>Asterixis</u> is a <u>negative</u> form of <u>myoclonus</u> in which a patient is suddenly, but briefly , unable to hold the arms and hands up against gravity, resulting in an erratic and repetitive <u>downward</u> jerking movement

Both are signs of central nervous system dysfunction

The <u>etiologic categories</u> of myoclonus are physiologic, essential, epileptic, and symptomatic:

* <u>Physiologic</u>: hypnic jerks (sleep starts), anxiety and exercise induced

* Essential

* <u>Epileptic</u>: primary generalized epilepsies (e.g., juvenile myoclonic epilepsy), myoclonic epilepsies

(often associated with progressive encephalopathy e.g., Lafora body disease, Unverrricht-Lundborg disease, sialidosis)

* <u>Symptomatic</u>: metabolic encephalopathy (uremia, liver failure, hypercapnia), Wilson disease, Creutzfeldt-Jakob disease and other advanced dementias, hypoxic

(post-anoxic brain injury or Lance-Adams syndrome)

<u>Physiologic myoclonus</u> includes common movements such as jerks that occur just <u>at sleep onset(</u> " sleep starts" or " hypnic jerks") and <u>hiccups</u>

<u>Essential myoclonus</u> occurs in isolation without other neurologic symptoms or signs. It may occur in <u>familial</u> and <u>sporadic</u> forms and may be <u>responsive</u> to small quantities of <u>alcohol</u> <u>Epileptic myoclonus</u> occurs as a manifestation of juvenile myoclonic epilepsy and other "<u>benign</u>" epilepsy syndromes, and with some of the more malignant progressive myoclonic epilepsies

<u>Symptomatic myoclonus</u> accompanies a wide variety of <u>metabolic</u> disturbances and <u>neurodegenerative</u> diseases

<u>Clonazepam</u> and <u>valproate</u> are often effective in controlling myoclonus, but an <u>underlying source</u> should be <u>identified</u> and <u>treated</u> if possible

VIII) <u>Tics</u>

Tics are <u>abnormal</u>, <u>brief muscle</u> <u>contractions</u> that may involve the face, extremities, or speech

They tend to <u>vary</u> in <u>intensity</u> and are <u>irregular</u> in <u>frequency</u>, sometimes occurring in runs of multiple tics and often <u>suppressible</u> for <u>short periods</u> of <u>time</u>

Patients with tics describe an <u>internal sensation</u> of an <u>urge</u> to <u>move</u> or perform the tic, with a sense of <u>relief after</u> the <u>tic</u> has <u>occurred</u>

<u>Stress</u> tends to <u>exacerbate</u> <u>tics</u>

Tics can be divided into motor and vocal tics

These, in turn can be divided into <u>simple</u> and <u>complex</u> tics

<u>Simple motor tics</u> involve eye blinks, facial grimaces, and shoulder shrugs

<u>Complex motor tics</u> include spitting and finger cracking

Examples of <u>simple vocal tics</u> include grunting, throat clearing, and coughing

<u>Complex vocal tics</u> are more extensive vocal utterances of several words blurted out, including <u>foul</u> <u>language</u> (<u>coprolalia</u>) <u>Tics</u> are most <u>often</u> <u>idiopathic</u>, but head trauma, encephalitis, and cerebrovascular disease may produce tics

<u>Gilles</u> de la <u>Tourette</u> syndrome is a pediatric-onset disorder in which patients develop motor and vocal tics It has a presumed genetic origin, but a single responsible gene mutation has not been identified Boys tend to be affected more often than girls Multiple motor and vocal tics are present; they may change over time and even go into periods of *remission* There is a tendency for tics to improve in adulthood Obsessive-compulsive disorder, attention- deficit hyperactivity disorder, and depression often accompany Tourette syndrome

<u>Pediatric autoimmune neuropsychiatric disorders</u> <u>associated</u> with <u>streptococcal infections</u> (<u>PANDAS</u>) are a combination of tics, obsessive-compulsive disorder, and anxiety <u>following group A beta-hemolytic</u> <u>streptococcal infection</u>

The <u>etiology</u> of PANDAS is <u>controversial</u>, but presumably the <u>streptococcal</u> <u>infection</u> triggers an <u>autoimmune</u> <u>reaction</u> against the <u>basal</u> <u>ganglia</u>

The <u>symptoms</u> are <u>temporary</u> and respond to treatment with antibiotics and immunomodulatory therapy <u>Tic treatment options</u> include dopamine antagonists (haloperidol, risperidone, and pimozide are used most commonly), guanfacine, clonazepam, and clonidine

In many cases, <u>tics</u> <u>improve</u> <u>during</u> <u>youth</u> and disappear by the <u>teenage</u> <u>years</u> or <u>early</u> <u>adulthood</u>